CellTrend received the European patent for antibodies against EGF (EP 3102945)
The results of the present examples show that anti-EGF antibody levels are significantly lower in patients with ovarian cancer compared to healthy controls. In addition, levels are significantly higher in patients who do not relapse after treatment with panitumumab or chemotherapeutic agents. Levels of anti-EGF antibodies in samples are a well-suited predictor of response to…